Zymeworks Inc (ZYM)
ZYM
Bispecific Antibody
BiotechSign Signal Grade
F
Signal Grade
28.6/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Clinical Activity
46
Pipeline Overview
- Therapeutic Focus
- Bispecific Antibodysrc
Clinical Trial Activity
4
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
2 Phase 1, 1 Phase 2, 1 Phase 3
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Zymeworks Inc.
Full ZYM Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.